High-sensitivity C-reactive protein (hs-CRP) is a blood test that measures very low levels of C-reactive protein, a marker your liver produces in response to inflammation. The test is primarily used to assess cardiovascular risk, with levels below 1.0 mg/L considered low risk, 1.0 to 3.0 mg/L average risk, and above 3.0 mg/L high risk. Unlike a standard CRP test, which detects infection or acute illness, the hs-CRP test is sensitive enough to pick up the kind of chronic, low-grade inflammation that drives heart disease over years.
How It Differs From a Standard CRP Test
CRP itself isn’t new. Doctors have used standard CRP tests for decades to detect infections, autoimmune flares, and other sources of obvious inflammation. But those tests have a minimum detection range starting around 5 mg/L, which means they miss anything below that threshold. For someone who’s otherwise healthy, CRP levels are typically well under 5 mg/L, so a standard test would simply read as “normal” even if meaningful inflammation were present.
The hs-CRP test can detect levels as low as 0.15 mg/L. This precision matters because in the late 1990s, researchers discovered that chronic low-grade inflammation plays a central role in atherosclerosis, the buildup of plaque inside arteries. Catching inflammation at these subtle levels gives doctors a way to identify cardiovascular risk that cholesterol numbers alone can miss.
What CRP Actually Is
C-reactive protein is produced by liver cells. Under normal conditions, the liver makes a small baseline amount. But when your body detects a threat, whether that’s an infection, tissue damage, or an autoimmune reaction, immune cells release signaling molecules called cytokines, particularly IL-1β and IL-6. These cytokines tell the liver to ramp up CRP production dramatically.
This makes CRP part of your body’s early warning system. It rises quickly in response to inflammation and drops once the trigger resolves. In acute situations like a bacterial infection or major injury, CRP can spike into the hundreds. In the context of cardiovascular risk, though, the relevant range is much smaller: the difference between 0.5 mg/L and 3.5 mg/L can signal a meaningfully different level of ongoing arterial inflammation.
The Three Risk Categories
The American Heart Association and CDC established three tiers for interpreting hs-CRP results in the context of heart disease risk:
- Low risk: below 1.0 mg/L
- Average risk: 1.0 to 3.0 mg/L
- High risk: above 3.0 mg/L
If your result comes back at 10 mg/L or higher, that typically signals an active infection or acute inflammation unrelated to cardiovascular risk. In that case, the test should be repeated once the infection has cleared to get an accurate baseline reading.
These categories aren’t meant to stand alone. Your doctor will interpret hs-CRP alongside other risk factors like cholesterol, blood pressure, smoking status, and family history. The value of the test is that it adds a dimension those traditional markers don’t capture.
Why It Matters for Heart Disease
One of the most striking demonstrations of hs-CRP’s importance came from the JUPITER trial, published through the American Heart Association. Researchers enrolled nearly 18,000 people who had low cholesterol but hs-CRP levels above 2 mg/L. Under existing guidelines, these people wouldn’t have qualified for statin therapy because their cholesterol looked fine. But when half the group received a statin, the results were dramatic: a 44% reduction in major cardiovascular events, a 54% reduction in heart attacks, and a 48% reduction in strokes. The trial was stopped early because the benefit was so clear.
Participants who achieved both low cholesterol and hs-CRP below 2 mg/L saw a 65% reduction in cardiovascular events. Those who reached hs-CRP below 1 mg/L with low cholesterol saw a 79% reduction. This suggests that lowering inflammation, not just cholesterol, is a key part of reducing heart disease risk.
Research from the Multi-Ethnic Study of Atherosclerosis added another layer. Over 13.6 years of follow-up, elevated levels of a genetic cholesterol particle called lipoprotein(a) only increased cardiovascular risk when hs-CRP was also 2 mg/L or higher. When hs-CRP was below 2 mg/L, even high lipoprotein(a) didn’t carry significant risk. Inflammation, in other words, seems to be the catalyst that turns other risk factors into actual events.
The Link to Metabolic Syndrome and Diabetes
Hs-CRP doesn’t just predict heart attacks. It tracks closely with metabolic syndrome, a cluster of conditions that includes abdominal obesity, high blood sugar, high triglycerides, low HDL cholesterol, and high blood pressure. In a large study of women, CRP levels rose in a nearly perfect staircase pattern as the number of metabolic syndrome features increased. Women with none of the five features had a median CRP of 0.68 mg/L. Those with all five had a median of 5.75 mg/L.
CRP is also an independent predictor of developing type 2 diabetes. This makes sense biologically: insulin resistance and atherosclerosis appear to share common inflammatory pathways. A rising hs-CRP level can signal metabolic trouble before blood sugar numbers cross into the diabetic range, and it correlates with other hard-to-measure markers like fasting insulin levels and early kidney stress.
What Lowers hs-CRP
The most effective approach for most people is lifestyle change, particularly weight loss combined with exercise. In the Look AHEAD trial, participants with type 2 diabetes who increased moderate-intensity exercise to 175 minutes per week and reduced caloric and saturated fat intake saw their hs-CRP drop by 43.6% over one year. The comparison group, which received only basic education, saw a 16.7% reduction. The intervention group lost an average of 8.8% of their body weight, improved their fitness by 19%, and saw benefits across triglycerides and HDL cholesterol as well.
A similar pattern appeared in the Diabetes Prevention Program, where obese participants at risk for diabetes who made diet and exercise changes lost about 7% of their body weight and reduced hs-CRP by roughly 30% in one year. The placebo group saw their CRP either stay flat or increase. Weight loss appears to be the single strongest driver of hs-CRP reduction through lifestyle, though exercise independently improves inflammation even when weight doesn’t change dramatically.
For people whose cardiovascular risk remains high despite lifestyle changes, statins lower both cholesterol and CRP through separate mechanisms. The JUPITER trial showed that the benefit of statins was greatest in people who achieved low levels of both markers, reinforcing that inflammation control matters alongside cholesterol management.
Getting the Test
An hs-CRP test is a simple blood draw. You don’t need to fast unless your doctor is also running a lipid panel at the same time. Because CRP can spike temporarily from a cold, minor injury, or dental work, most guidelines recommend testing twice, about two weeks apart, and using the average of the two results for risk assessment. This reduces the chance of a one-time spike giving a misleading picture.
The test is most useful for people at intermediate cardiovascular risk, where the result could genuinely change the treatment decision. If you already have clearly high cholesterol and multiple risk factors, you’re likely getting treated regardless. If you’re young with no risk factors, the test adds little. The sweet spot is the gray zone: people whose traditional risk factors put them somewhere in the middle, and where knowing their inflammation status could tip the balance toward more aggressive prevention.